CyberKnife Radiosurgery for Localized Prostatic Carcinoma

Sponsor
CyberKnife Centers of San Diego (Other)
Overall Status
Unknown status
CT.gov ID
NCT01045148
Collaborator
(none)
258
1
1

Study Details

Study Description

Brief Summary

Virtual high dose rate (HDR) CyberKnife (CK) prostate treatment has comparable morbidity and efficacy compared with actual prostate HDR treatment, but does it without the catheters and hospital admission. As such, it is a more "patient friendly" treatment method compared with actual prostate HDR brachytherapy as currently practiced. Related, as has previously been reported with actual prostate HDR treatment, Virtual HDR CyberKnife prostate treatment should have a high efficacy but with lower acute and chronic morbidity compared with other local prostate cancer treatment methods such as permanent seed prostate brachytherapy.

Condition or Disease Intervention/Treatment Phase
  • Radiation: CyberKnife Radiosurgery
  • Radiation: CyberKnife Radiosurgery
Phase 2

Detailed Description

Brachytherapy is a form of treatment where a radioactive isotope is implanted directly into a tumor volume to deliver a lethal dose of radiation. High Dose Rate (HDR) Prostate brachytherapy is a particularly elegant brachytherapy dose sculpting method that is effectively used in the curative treatment of prostate cancer; however, it requires hospital admission and many temporarily implanted transperineal catheters to deliver the radiation source to the target volume, resulting in significant patient discomfort. CyberKnife delivers a form of radiation treatment that is so precise, it appears capable of reconstructing HDR prostate radiation dose sculpting, without the hospital admission and without the catheters. The CyberKnife device is also used for classic radiosurgery, with accuracy comparable to the Gamma Knife, but unlike the Gamma Knife, has the capability to target lesions anywhere in the body with similar accuracy. The aim of this study is to compare CyberKnife morbidity and efficacy with that of HDR and other local treatment methods such a permanent seed prostate brachytherapy in the treatment of prostate cancer.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
258 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Virtual HDR CyberKnife Radiosurgery for Localized Prostatic Carcinoma: A Phase II Study
Study Start Date :
Mar 1, 2006
Anticipated Primary Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Other: CyberKnife Radiosurgery

CyberKnife Radiosurgery

Radiation: CyberKnife Radiosurgery
High Dose 3800 cGy/4 fractions

Radiation: CyberKnife Radiosurgery
Moderate Dose 3400 cGy/5 fractions

Outcome Measures

Primary Outcome Measures

  1. To evaluate the effects of CK prostate radiosurgery in terms of morbidity/QOL, relative to other commonly used methods of prostate cancer treatment and the pattern of PSA decline and biochemical relapse-free survival thereafter. [5 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Histologically confirmed adenocarcinoma of the prostate, clinical stage T1b - T2b (AJCC 6th Edition, see Appendix II), NX/N0, M0.

  • Karnofsky performance status > 80.

  • Patient must be ≥ 18 years of age.

  • Gleason Sum < or = 7

  • Prostate-specific antigen < or = 20 ng/ml

  • Patients must sign a study-specific informed consent form prior to study entry.

Exclusion Criteria:
  • Stage < T1b, T2c, T3 or T4 disease (AJCC 6th Edition, see Appendix II).

  • Gleason Score > 7.

  • PSA > 20 ng/ml.

  • Lymph node involvement (N1).

  • Evidence of distant metastases (M1).

  • Radical surgery for carcinoma of the prostate, prior pelvic radiation, pelvic surgical clips or other metallic foreign bodies.

  • History of hormonal therapy (antiandrogen or 5 alpha reductase treatment within three months prior to treatment).

  • Previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ≥ 5 years.

  • Major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up.

  • Metallic Hip prosthesis.

  • History of inflammatory bowel disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 CyberKnife Centers of San Diego San Diego California United States 92024

Sponsors and Collaborators

  • CyberKnife Centers of San Diego

Investigators

  • Principal Investigator: Donald B Fuller, M.D., CyberKnife Centers of San Diego/Radiation Medical Group- Genesis Healthcare Partners

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Carlyn Tripp, Donald Fuller, M.D., CyberKnife Centers of San Diego
ClinicalTrials.gov Identifier:
NCT01045148
Other Study ID Numbers:
  • Virtual HDR CK Radiosurgery
First Posted:
Jan 8, 2010
Last Update Posted:
Jul 21, 2017
Last Verified:
Jul 1, 2017
Keywords provided by Carlyn Tripp, Donald Fuller, M.D., CyberKnife Centers of San Diego
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 21, 2017